Non Motor Symptoms Treatment In Parkinson'S Disease is a treatment approach for neurodegenerative diseases. This page provides comprehensive information about its mechanism of action, clinical evidence, and therapeutic potential.
{{Infobox
|title=Non-Motor Symptoms Treatment in Parkinson's Disease
|category=Treatment
|target=Parkinson's Disease
|status=Standard of Care
|phase=Approved
}}
Non-motor symptoms affect up to 90% of PD patients and include:
- Depression and anxiety
- Psychosis and hallucinations
- Sleep disorders
- Autonomic dysfunction
- Cognitive impairment
- Sensory symptoms
¶ Depression and Anxiety
- First-line: SSRIs (sertraline, escitalopram, citalopram)
- SNRIs: Venlafaxine, duloxetine
- TCAs: Nortriptyline (caution for orthostatic hypotension)
- Dopamine agonists: May improve mood in some patients
- ECT: For severe, treatment-resistant depression
¶ Psychosis and Hallucinations
-
Pimavanserin (Nuplazid): FDA-approved for PD psychosis
- 5-HT2A inverse agonist
- No worsening of motor symptoms
- 34% reduction in SAPS scores
-
Quetiapine: Off-label, first-line antipsychotic
- Low D2 receptor occupancy
- Dose: 12.5-150 mg at bedtime
-
Clozapine: Most effective but requires ANC monitoring
- Dose: 6.25-50 mg
- Weekly ANC for first 6 months
- Dopamine agonist dose adjustment
- Methylphenidate for severe cases
- SSRIs may worsen apathy
- Melatonin: 3-12 mg at bedtime
- Clonazepam: 0.25-1 mg at bedtime (first-line)
- Pramipexole: May help RBD in some patients
- Modafinil: 100-400 mg daily
- Methylphenidate: 5-10 mg BID
- Caffeine: 100-200 mg TID
- Sleep hygiene optimization
- Cognitive behavioral therapy (CBT-I)
- Sleep hygiene
- Rotigotine patch may improve sleep continuity
- Midodrine: 2.5-10 mg TID
- Fludrocortisone: 0.1-0.2 mg daily
- Droxidopa (Northera): 100-600 mg TID
- Increased salt and fluid intake
- Compression stockings
- Head-of-bed elevation
- Detrol/toIterodine: Anticholinergic for overactive bladder
- Mirabegron: Beta-3 agonist
- Catheterization: For severe retention
- Constipation: Fiber, laxatives,lubiprostone
- Nausea: Domperidone, ondansetron
- Dysphagia: Swallowing therapy, botox
- Sildenafil for erectile dysfunction
- Hormone replacement if deficient
- Dose adjustment of dopaminergic medications
- Rivastigmine may help
- Exercise and cognitive training
- Management of mood symptoms
-
Cholinesterase inhibitors: Rivastigmine (first-line)
- Transdermal patch: 4.6-13.3 mg/24h
- Oral: 1.5-12 mg daily
-
Memantine: May provide modest benefit
-
Donepezil: Mixed evidence in PDD
¶ Pain and Dysesthesia
- Gabapentin: 300-1800 mg daily
- Pregabalin: 75-300 mg BID
- Duloxetine: 30-60 mg daily
- Physical therapy
- Intranasal theophylline: Trial ongoing
- Smell training therapy
- SSRIs + MAO-B inhibitors: Serotonin syndrome risk
- Anticholinergics: Cognitive worsening
- QT-prolonging agents: Cardiac risk with pimavanserin
- Identify and treat underlying causes
- Optimize dopaminergic therapy
- Target specific symptoms
- Non-pharmacological interventions
- Multidisciplinary care
The study of Non Motor Symptoms Treatment In Parkinson'S Disease has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
[1] Schapira AHV, et al. Nat Rev Dis Primers. 2023;9(1):21. PMID:36958789
[2] Seppi K, et al. Mov Disord. 2019;34(7):991-1026. PMID:31346586
[3] Goldman JG, et al. Nat Rev Neurol. 2018;14(10):577-588. PMID:30140230
[4] Poewe W, et al. Nat Rev Dis Primers. 2017;3:17013. PMID:28303888
[5] Martinez-Martin P, et al. Lancet Neurol. 2024;23(1):54-68. PMID:38101675
[6] Chaudhuri KR, et al. Nat Rev Neurol. 2023;19(2):73-84. PMID:36564601
[7] Weintraub D, et al. Mov Disord. 2020;35(5):816-825. PMID:32162636
[8] Kalia LV, et al. Lancet. 2015;386(9996):896-912. PMID:25950610